Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature

World Journal of Surgical Oncology

Sumeng Wang¹  Yiqian Liu¹  Xian Xu¹  Lingxiang Liu¹  Qi Liang¹  Shanyue Tan¹  Huanhuan Xu¹ 

[1]Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, 210029, Nanjing, Jiangsu, People’s Republic of China

关键词: Afatinib;    Anlotinib;    HER2 mutation;    Lung adenocarcinoma;    Targeted therapy;   

DOI  :  10.1186/s12957-021-02444-7

来源: Springer

【 摘 要 】

BackgroundHER2 is a member of the ERBB family of receptor tyrosine kinases, and HER2 mutations occur in 1–4% of non-small cell lung cancer (NSCLC) as an oncogenic driver mutation. We found a rare mutation of HER2 p.Asp769Tyr in NSCLC.Case presentationWe presented a case of a 68-year-old nonsmoking male patient with brain metastasis from lung adenocarcinoma harboring a rare mutation of HER2 p.Asp769Tyr. After multiple lines of treatment, he obtained a durable response (10 months) to afatinib and anlotinib.ConclusionWe reported for the first time that afatinib and anlotinib have successfully treated lung adenocarcinoma with HER2 p.Asp769Tyr mutation. This finding can provide an insight into the optimal treatment of lung adenocarcinoma patients with novel mutations. Additionally, we summarized the efficacy of targeted therapy for HER2 mutant lung cancer in this article.

【 授权许可】

CC BY